Can We Define Asthma-COPD Overlap (ACO) by Biomarkers?
Publication date: January 2019Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 7, Issue 1Author(s): Kenji Izuhara, Peter J. Barnes
Early accurate diagnosis and sustainable availability of affordable medicines and diagnostic tests is fundamental in optimal management of asthma and chronic obstructive pulmonary disease (COPD). We systematic...
ConclusionWhile most PCPs and respiratory/allergy specialists can reach a working diagnosis of ACO, there remains uncertainty around which diagnostic features are most important and what constitutes optimal management. It is imperative that clinical studies including patients with ACO are initiated, allowing the generation of evidence ‐based management strategies.This article is protected by copyright. All rights reserved.
The World Health Organization estimates that at least 300 million people suffer from asthma worldwide.1 Over 17.7 million adults suffer from asthma compared to the 6.3 million children who are also afflicted with asthma in the United States (U.S.).2 Older adults ages 65 and over with asthma are the fastest growing age-group in the U.S.3 Studies in the United States show that asthma and other reactive airway diseases are under-diagnosed among the elderly, that asthma-related morbidity and mortality among the elderly is increasing4 and that nationally the number of older adults dying from asthma is 14 times higher compared t...
Millions of Americans suffer from respiratory diseases, including Asthma and chronic obstructive pulmonary disease (COPD). Together, these two diseases affect the day-to-day lives of over 40 million patients in the U.S. Furthermore, respiratory allergies affect 10 percent of children under the age of 18. Not only do these diseases impact day-to-day functioning, but they can also be life-threatening.
Conclusion: GRNX effectively treated asthma and COPD patients with acute bacterial infection without severe adverse events. Further research with a larger study population is needed.Int Arch Allergy Immunol
Chronically inflamed airways in asthma and chronic obstructive pulmonary disease (COPD) are susceptible to heightened neutrophilic inflammation but the underlying mechanisms are unclear. We previously showed that SP-D deficiency is associated with increased and prolonged neutrophilic inflammation of the airways in mice. Extracellular release of double stranded DNA by neutrophils contributes to the inflammatory injury. We hypothesized that SP-D interferes with this process.
The effects of opioid use on respiratory conditions are mixed – while licit opiates help with cough and the dyspnea of heart disease and chronic obstructive pulmonary disease, illicit opiates may exacerbate asthma. We hypothesized that there would be an increased prevalence of asthma in patients with chronic opioid dependence.
Forced oscillation technique (FOT) has a potential to evaluate respiratory pathophysiology in asthma that spirometry does not detect. Since lung function decline in children with asthma has been reported to have significant impact on development of COPD in later life, we investigated changes in FOT parameters in children/adolescents with asthma in relation with changes in maximal expiratory flow at 50 % of the forced vital capacity (MEF50), an index for the small airways.
ConclusionThe Vilnius Declaration represents an important step for the fight against air pollution in chronic respiratory diseases globally and has a clear strategic relevance with regard to the EU Health Strategy as it will bring added value to the existing public health knowledge.
CONCLUSION: IL-17A is a major regulator of inflammatory responses. In all the mentioned diseases, IL-17A plays a prime role in inducing the diseases, whereas the lack of this pro-inflammatory cytokine reduces the severity of respective respiratory diseases. Thereby, this review suggests IL-17A as an instrumental target in the chronic respiratory diseases. PMID: 30652654 [PubMed - as supplied by publisher]